Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for <i>MTAP</i> -Deleted <i>KRAS</i> -Mutant Pancreatic Cancer

MTAP deletion and mutational activation of KRAS create therapeutic vulnerabilities for MTA-cooperative PRMT5 and mutant-selective KRAS inhibitors, respectively, providing the rationale for their combination therapy for MTAP-deleted, KRAS-mutant pancreatic cancer. See related article by Knoll et al., p. 3518.